Literature DB >> 14989361

The immunoregulation of mice by somatic transgenic expression of porcine interleukin-6 gene and CpG sequence.

Jiangling Li1, Rong Gao, Mei Wu, Mingjie Meng, Manshu Tang, Yi Shen, Lihuan Wang, Xueyan Wu, Xue Yin, Hongguan Xie, Shigui Liu.   

Abstract

Porcine IL-6 gene and CpG sequences were used to enhance some indirect indicators of the immune response of mice. An indirect ELISA was used to quantify the amount of IgG in the sera from mice that had been inoculated with VPIL-6, a recombinant VR1020 vector into which had been inserted the porcine IL-6 gene cloned in our laboratory, or with CpG, pUC18 or VR1020. The induced bioactivity of IL-2 of lymphocytes in the spleen was assayed by the MTT method, and the proliferation of lymphocytes stimulated with ConA was tested to identify the immune response of the experimental mice. The amount of IgG in the immunized mice was significantly higher than that in the control group. Among the immunized groups, inoculation with VPIL-6 induced the highest content of IgG (p < 0.05), the greatest bioactivity of IL-2 and the greatest proliferation of lymphocytes from the spleen of the mice. These results suggest that inoculation with porcine IL-6 gene and CpG sequences may enhance the immune response of mice, and might be used as an immunoadjuvant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14989361     DOI: 10.1023/b:verc.0000009530.93517.b6

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.816


  23 in total

1.  Purification of plasmid DNA using selective precipitation by compaction agents.

Authors:  J C Murphy; J A Wibbenmeyer; G E Fox; R C Willson
Journal:  Nat Biotechnol       Date:  1999-08       Impact factor: 54.908

2.  Studies of immunity and bacterial invasiveness in mice given a recombinant salmonella vector encoding murine interleukin-6.

Authors:  S J Dunstan; A J Ramsay; R A Strugnell
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Contribution of CpG motifs to the immunogenicity of DNA vaccines.

Authors:  D M Klinman; G Yamshchikov; Y Ishigatsubo
Journal:  J Immunol       Date:  1997-04-15       Impact factor: 5.422

4.  Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids.

Authors:  M Geissler; A Gesien; K Tokushige; J R Wands
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

5.  Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Authors:  G Hartmann; R D Weeratna; Z K Ballas; P Payette; S Blackwell; I Suparto; W L Rasmussen; M Waldschmidt; D Sajuthi; R H Purcell; H L Davis; A M Krieg
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

6.  Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine.

Authors:  I S Leal; B Smedegârd; P Andersen; R Appelberg
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 7.  DNA vaccination against influenza viruses: a review with emphasis on equine and swine influenza.

Authors:  C W Olsen
Journal:  Vet Microbiol       Date:  2000-05-22       Impact factor: 3.293

8.  Immunostimulatory DNA sequences necessary for effective intradermal gene immunization.

Authors:  Y Sato; M Roman; H Tighe; D Lee; M Corr; M D Nguyen; G J Silverman; M Lotz; D A Carson; E Raz
Journal:  Science       Date:  1996-07-19       Impact factor: 47.728

9.  IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells.

Authors:  M Okada; M Kitahara; S Kishimoto; T Matsuda; T Hirano; T Kishimoto
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

10.  CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus.

Authors:  Z Moldoveanu; L Love-Homan; W Q Huang; A M Krieg
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.